Loading Page
Dr. Patience Ifeyinka Odeniyide, MD, PhD is a medical oncologist in Baltimore, MD specializing in medical oncology and hematology (blood disorders). She graduated from Indiana University School of Medicine in 2014 and has 12 years of experience. Dr. Patience Ifeyinka Odeniyide, MD, PhD is affiliated with Johns Hopkins Children's Center and Pediatric Specialists of Virginia.
Dr. Patience Ifeyinka Odeniyide, MD, PhD graduated from Indiana University School of Medicine in 2014. She completed residency at University of North Carolina (UNC) Affiliated Hospitals. She is certified by the Board Certification: Pediatric Hematology/Oncology, General Pediatrics and has a state license in Maryland.
Medical School: Indiana University School of Medicine (2014)
Residency: University of North Carolina (UNC) Affiliated Hospitals (2017)
Board Certification: Board Certification: Pediatric Hematology/Oncology, General Pediatrics
Licensed In: Maryland
Dr. Patience Ifeyinka Odeniyide, MD, PhD is associated with these hospitals and organizations:
Dr. Patience Ifeyinka Odeniyide, MD, PhD does not have any reviews yet, be the first to leave a review of Dr. Patience Ifeyinka Odeniyide, MD, PhD here: Leave a Review
Dr. Odeniyide is an Assistant Professor in the Division of Pediatric Oncology. Her research focuses on RAS-directed therapies for pediatric rhabdomyosarcoma and her clinical expertise is in the treatment of pediatric solid tumors. Dr. Odeniyide received her undergraduate degree from the University of North Carolina at Chapel Hill and earned her MD from Indiana University School of Medicine. She did her general pediatric residency at the University of North Carolina at Chapel Hill and completed her pediatric hematology/oncology fellowship at Johns Hopkins/ NIH Pediatric Oncology Branch Pediatric Hematology/Oncology joint fellowship training program in 2017. She completed her Ph.D. in cellular and molecular medicine at Johns Hopkins School of Medicine in 2022. Dr. Odeniyide aims to develop and implement novel molecularly targeted therapeutics to treat pediatric cancers with genetic alterations. Her research is focused on the application of small molecule therapeutics for tumors with RAS mutations, a common mutation in cancer for which few effective targeted therapies exist. Her goal is that her research will bring more effective therapeutic options for pediatric sarcoma patients.
